SG11201603119RA - Oncolytic hsv vector - Google Patents

Oncolytic hsv vector

Info

Publication number
SG11201603119RA
SG11201603119RA SG11201603119RA SG11201603119RA SG11201603119RA SG 11201603119R A SG11201603119R A SG 11201603119RA SG 11201603119R A SG11201603119R A SG 11201603119RA SG 11201603119R A SG11201603119R A SG 11201603119RA SG 11201603119R A SG11201603119R A SG 11201603119RA
Authority
SG
Singapore
Prior art keywords
hsv vector
oncolytic hsv
oncolytic
vector
hsv
Prior art date
Application number
SG11201603119RA
Inventor
Hiroaki Uchida
Justus Cohen
Iii Joseph C Glorioso
Paola Grandi
Original Assignee
Univ Pittsburgh
Hiroaki Uchida
Justus Cohen
Iii Joseph C Glorioso
Paola Grandi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh, Hiroaki Uchida, Justus Cohen, Iii Joseph C Glorioso, Paola Grandi filed Critical Univ Pittsburgh
Publication of SG11201603119RA publication Critical patent/SG11201603119RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/763Herpes virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661Methods of inactivation or attenuation
    • C12N2710/16662Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671Demonstrated in vivo effect
SG11201603119RA 2013-10-28 2014-10-28 Oncolytic hsv vector SG11201603119RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896497P 2013-10-28 2013-10-28
PCT/US2014/062676 WO2015066042A1 (en) 2013-10-28 2014-10-28 Oncolytic hsv vector

Publications (1)

Publication Number Publication Date
SG11201603119RA true SG11201603119RA (en) 2016-05-30

Family

ID=53005031

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603119RA SG11201603119RA (en) 2013-10-28 2014-10-28 Oncolytic hsv vector

Country Status (18)

Country Link
US (5) US10201575B2 (en)
EP (3) EP3063279B1 (en)
JP (3) JP6588024B2 (en)
KR (2) KR102490462B1 (en)
CN (2) CN113717952A (en)
AU (1) AU2014342465B2 (en)
BR (1) BR112016009465A8 (en)
CA (1) CA2928956A1 (en)
DK (1) DK3184641T3 (en)
ES (2) ES2781852T3 (en)
HK (1) HK1225756A1 (en)
IL (2) IL245312B (en)
MX (2) MX2016005488A (en)
NZ (1) NZ720021A (en)
PT (1) PT3184641T (en)
RU (1) RU2719190C2 (en)
SG (1) SG11201603119RA (en)
WO (1) WO2015066042A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
ES2781852T3 (en) 2013-10-28 2020-09-08 Univ Pittsburgh Commonwealth Sys Higher Education Oncolytic HSV vector
HUE054563T2 (en) * 2015-02-11 2021-09-28 Univ Bologna Alma Mater Studiorum Retargeted herpesvirus with a glycoprotein h fusion
JP2019508063A (en) 2016-01-27 2019-03-28 オンコラス, インコーポレイテッド Oncolytic virus vector and use thereof
IL261713B2 (en) * 2016-03-19 2023-09-01 F1 Oncology Inc Methods and compositions for transducing lymphocytes and regulated expansion thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
EP3712273A1 (en) * 2016-04-08 2020-09-23 Krystal Biotech, LLC Compositions for the treatment of wounds, disorders, and diseases of the skin
IL262385B2 (en) 2016-04-22 2024-01-01 Immvira Co Ltd CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
ES2904882T3 (en) * 2016-04-29 2022-04-06 Virogin Biotech Canada Ltd HSV vectors with enhanced replication in cancer cells
KR20190020727A (en) 2016-06-09 2019-03-04 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 Herpes virus with modified glycoprotein B
ES2862531T3 (en) 2016-06-09 2021-10-07 Univ Bologna Alma Mater Studiorum Herpes virus with modified D glycoprotein
EP3468588A4 (en) * 2016-06-14 2019-12-11 University of Pittsburgh - of The Commonwealth System of Higher Education Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
RU2021127872A (en) 2016-06-30 2021-11-09 Онкорус, Инк. DELIVERY OF THERAPEUTIC POLYPEPTIDES THROUGH PSEUDOTYPED ONCOLYTIC VIRUSES
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP3577132A4 (en) * 2017-02-03 2021-03-10 University of Pittsburgh - of The Commonwealth System of Higher Education Oncolytic virus therapy
CN115820571A (en) * 2017-03-09 2023-03-21 厦门大学 Recombinant herpes simplex virus and application thereof
CA3070299A1 (en) * 2017-07-26 2019-01-31 Oncorus, Inc. Oncolytic viral vectors and uses thereof
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
US20210177921A1 (en) * 2017-11-16 2021-06-17 Virogin Biotech Canada Ltd Targeting moiety-decorated oncolytic viruses
JP2021508477A (en) 2017-12-29 2021-03-11 オンコラス, インコーポレイテッド Oncolytic virus delivery of therapeutic polypeptides
MA52542A (en) * 2018-04-13 2021-02-24 Bluebird Bio Inc ADOPTIVE CELL THERAPY
AU2019277669A1 (en) * 2018-05-31 2020-12-17 Trustees Of The University Of Pennsylvania Antigenically stealthed oncolytic viruses
KR101998793B1 (en) * 2018-09-04 2019-07-10 의료법인 성광의료재단 A vector for preparing recombinant herpes simplex virus
CN111117973A (en) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 Recombinant oncolytic enterovirus 71 regulated and controlled by microRNA and application thereof
TW202038947A (en) 2018-11-28 2020-11-01 德商創新分子有限責任公司 Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
WO2021072310A1 (en) 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
KR20210151002A (en) * 2020-06-03 2021-12-13 주식회사 젠셀메드 Recombinant Herpes Simplex Virus Containing Expression Cassette Expressing a Fused Protein of Extracellular Damain of HveC and Tumor Cell-targeting Domain and Use of the Same
KR102418528B1 (en) * 2020-06-12 2022-07-11 주식회사 젠셀메드 Recombinant Herpes Simplex Virus Containing Expression Cassette Expressing a Fused Protein of Tumor Cell-targeting Domain and Extracellular Damain of HVEM and Use of the Same
JP7235334B2 (en) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド Construction of oncolytic herpes simplex virus (oHSV) obligate vectors and their constructs for cancer therapy
CA3213789A1 (en) 2021-04-02 2022-10-06 Krystal Biotech, Inc. Viral vectors for cancer therapy
TW202342758A (en) * 2022-01-29 2023-11-01 加拿大商復諾健生物科技加拿大有限公司 Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (en) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 Recombinant plasmid with herpes simplex virus gene
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
WO1999031241A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
ATE508635T1 (en) * 2001-03-27 2011-05-15 Catherex Inc VIRUS VECTORS AND THEIR USE IN THERAPEUTIC METHODS
PL373594A1 (en) 2001-10-04 2005-09-05 Immunex Corporation Ul16 binding protein 4
KR100900249B1 (en) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 SIVmac239 Immunogenic Plasmids And AIDS DNA Vaccine Containing The Same
WO2003073918A2 (en) 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP2377882A1 (en) 2004-10-28 2011-10-19 University of Pittsburgh of the Commonwealth System of Higher Education Peripherally delivered glutamatic acid decarboxylase gene therapy for spinal cord injury pain
US10000757B2 (en) 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8586028B2 (en) 2007-05-09 2013-11-19 Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
DK2700405T3 (en) * 2008-05-29 2018-05-22 Univ Bologna Alma Mater Studiorum Herpes simplex virus (HSV) with modified tropism, its uses and method of preparation
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
US8569065B2 (en) 2009-03-13 2013-10-29 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
WO2011125469A1 (en) 2010-04-09 2011-10-13 国立大学法人東京大学 Micro-rna-regulated recombinant vaccinia virus and utilization thereof
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
CN105637092B (en) 2013-07-17 2021-06-11 匹兹堡大学-属高等教育联邦体系 Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
ES2781852T3 (en) 2013-10-28 2020-09-08 Univ Pittsburgh Commonwealth Sys Higher Education Oncolytic HSV vector

Also Published As

Publication number Publication date
RU2016120618A3 (en) 2018-05-22
PT3184641T (en) 2020-08-21
KR20160108301A (en) 2016-09-19
RU2719190C2 (en) 2020-04-17
US10576115B2 (en) 2020-03-03
CN113717952A (en) 2021-11-30
US20190262410A1 (en) 2019-08-29
US10188686B2 (en) 2019-01-29
CA2928956A1 (en) 2015-05-07
US20160250267A1 (en) 2016-09-01
ES2781852T3 (en) 2020-09-08
JP2021180661A (en) 2021-11-25
EP3778906A1 (en) 2021-02-17
BR112016009465A8 (en) 2018-01-30
IL272480B (en) 2021-06-30
KR102490462B1 (en) 2023-01-19
US10172893B2 (en) 2019-01-08
MX2021001158A (en) 2021-04-28
WO2015066042A1 (en) 2015-05-07
RU2016120618A (en) 2017-12-06
EP3063279B1 (en) 2020-01-01
US11883448B2 (en) 2024-01-30
US10201575B2 (en) 2019-02-12
US20170035819A1 (en) 2017-02-09
US20170274025A1 (en) 2017-09-28
ES2810800T3 (en) 2021-03-09
CN106068326A (en) 2016-11-02
NZ720021A (en) 2022-08-26
JP6588024B2 (en) 2019-10-09
IL272480A (en) 2020-03-31
US20210138007A1 (en) 2021-05-13
KR20210145296A (en) 2021-12-01
JP2020058341A (en) 2020-04-16
HK1225756A1 (en) 2017-09-15
IL245312A0 (en) 2016-06-30
IL245312B (en) 2020-02-27
EP3063279A1 (en) 2016-09-07
EP3184641A1 (en) 2017-06-28
AU2014342465B2 (en) 2018-03-08
MX2016005488A (en) 2016-10-03
JP2016537020A (en) 2016-12-01
JP7262134B2 (en) 2023-04-21
EP3184641B1 (en) 2020-07-08
CN106068326B (en) 2021-06-18
KR102330183B1 (en) 2021-11-23
JP6919912B2 (en) 2021-08-18
BR112016009465A2 (en) 2017-10-03
AU2014342465A1 (en) 2016-06-02
DK3184641T3 (en) 2020-08-03
EP3063279A4 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
HK1225756A1 (en) Oncolytic hsv vector
HK1222302A1 (en) Dryer
EP2964517A4 (en) Rudder
HK1217316A1 (en) Photo-alignable object
SG11201504818PA (en) Fast ship
EP2987086A4 (en) Secure computing
HRP20180452T1 (en) Peptides
IL240319A (en) Rapid detection
GB201320692D0 (en) Solenoid-actuator-armature end-of-motion detection
PL2938239T3 (en) Hand dryer
GB201309845D0 (en) Containerised drier
GB201305366D0 (en) Improved suitcase
HK1221417A1 (en) Modified hydrogels
GB201315130D0 (en) Peptides
GB201300683D0 (en) Peptide
GB201310441D0 (en) Suitcase/sunlounger/campbed
GB201306435D0 (en) Vector
HK1208325A1 (en) Hand dryer
PL3074788T3 (en) Maneuver processing
GB201319425D0 (en) Hand drier
HUP1300431A2 (en) Bow
GB201316660D0 (en) Peptides
GB201315627D0 (en) Hand dryer
GB201308772D0 (en) Vectors
GB201314020D0 (en) Hand dryer